Feathered bioreactor: transforming a chicken egg into a recombinant protein biomanufacturing foundry Authors: Adnan Naim, Arjun Sharma, Sanket Kumar Ray, Debasis Nayak Published: 2026 ABSTRACT Highlights•The demand for recombinant protein-based therapeutics has increased.•Conventional recombinant protein production platforms have several limitations.•Chicken egg-based bioreactor systems offer a promising alternative.•Genome modified chickens produce therapeutic recombinant proteins like antibodies.Keywords: Recombinant protein, Bioreactor, Chicken egg, Primordial germ cell, Biomanufacturing Introduction In recent decades, the growing burden of chronic diseases including metabolic disorders, autoimmune conditions, cancer, heart diseases and diabetes has exposed the limitations of the traditionally synthesized small-molecule drugs, which often lack the target specificity required for safe and effective long-term management (Kintzing et al., 2016; Lagassé et al., 2017; Lu et al., 2020; Kinch et al., 2023). This unmet clinical need has driven the pharmaceutical industry towards recombinant protein-based biologics, including monoclonal antibodies, cytokines, vaccines and growth hormones, which offer superior specificity, efficacy, and reduced off-target toxicity compared to conventional small molecules (Ebrahimi and Samanta, 2023; Izutsu, 2024). Despite their remarkable therapeutic potential, the commercial realization of recombinant proteins remains constrained by the complexity of their production. Unlike small molecules, recombinant proteins require precise folding of polypeptide chains and accurate post-translational modifications, most critically glycosylation which collectively governs the protein function, immunogenicity, and in vivo stability (Zhang et al., 2016; Beygmoradi et al., 2023; Kumar et al., 2024; Rathore et al., 2024; Yoo et al., 2024). Compounding these biological challenges, downstream processing steps such as purification, formulation, and cold-chain logistics impose substantial infrastructure costs that place these therapeutics beyond the reach of healthcare systems in Low-and Middle-Income Countries (LMICs), where the burden of chronic disease is disproportionately high. There is therefore an urgent need for production platforms that are biologically capable, economically accessible, and scalable without dependence on high-cost bioreactor infrastructure. The chicken has emerged as a compelling candidate to meet this need. The natural ability of the chicken to secrete abundant proteins into the developing egg provides the biological basis and capabilities to utilize the chicken egg as a recombinant protein bioreactor—a feathered foundry with the potential to democratize access to life-saving biologics. (Farzaneh et al., 2017; Herron et al., 2018; Woodfint et al., 2018; Jung et al., 2024; Meng et al., 2025). Justification for high protein production The global biopharmaceutical sector has witnessed remarkable growth in the development and commercialization of protein-based therapeutics, including monoclonal antibodies, cytokines, enzymes, hormones, and recombinant vaccines (Gupta et al., 2017; Shukla et al., 2017; Kinch et al., 2023; Kumar et al., 2024; Liu et al., 2025). The global recombinant protein therapeutics market size was valued at USD 23.7 billion in 2024 and is expected to reach USD 76.94 billion by 2033, growing at an annual growth rate (AGR) of 13.95% (Business Research Insights). Parallel to this market, the U.S. Food and Drug Administration (USFDA) has approved hundreds of biologics in the past decade, and their increasing clinical application in oncology, autoimmune diseases, metabolic disorders, and infectious diseases continues to drive demand for production platforms that are simultaneously cost-effective, scalable and capable of producing structurally authentic human-compatible proteins (Senior, 2024). Meeting this demand requires expression systems that can faithfully replicate the post-translational processing of human proteins, particularly with respect to glycosylation while remaining economically viable at commercial scale. Existing production platform systems, from microbial systems to mammalian cell cultures, each offers limitations and biological fidelity and production economics. Understanding these trade-offs is essential for contextualizing the potential of the chicken egg as an alternative bioreactor, as illustrated in Fig. 1. The following section provides a comparative overview of the major expression systems currently in use. Comparison of major recombinant protein expression platforms highlighting the biological and manufacturing advantages of the chicken egg bioreactor relative to bacterial, yeast, insect, and mammalian systems. Existing bioreactor platforms for recombinant protein production: opportunities and limitations Recombinant therapeutic proteins are primarily produced in bacterial, yeast, insect, and mammalian expression systems, each offering distinct advantages and limitations in productivity, scalability, manufacturing cost, and post-translational modifications (PTMs). Consequently, the choice of platform depends on the structural complexity and intended clinical application of the target protein. Escherichia coli remains one of the most widely used microbial hosts because of its rapid growth, simple genetics, high productivity, and low production cost. It has enabled commercial production of proteins such as insulin and growth hormone. However, the lack of complex PTMs, particularly glycosylation, and the frequent formation of insoluble inclusion bodies restrict its suitability for many therapeutic glycoproteins (Rosano and Ceccarelli, 2014; İncir and Kaplan, 2025). Yeast systems, including Saccharomyces cerevisiae and Pichia pastoris, support protein secretion and selected eukaryotic PTMs while remaining cost-effective (Kim et al., 2015). Similarly, insect cell-baculovirus systems efficiently produce structurally complex proteins and virus-like particles (Sulek and Szuster-Ciesielska, 2025). Nevertheless, both platforms generate non-human glycosylation profiles that can influence protein activity, serum half-life, and immunogenicity (Rodríguez-Hernández et al., 2023; Hong et al., 2022; Meng et al., 2025). Chinese hamster ovary (CHO) cells remain the gold standard for manufacturing therapeutic glycoproteins because they closely reproduce human PTMs and glycosylation. However, slow growth, expensive culture media, complex bioprocessing, and high manufacturing costs substantially increase the cost of biologic medicines (Tan et al., 2021). Collectively, no conventional platform simultaneously offers low production costs, rapid scalability, high protein yield, and authentic human-like PTMs. These limitations have driven the development of alternative bioreactor systems, among which the avian egg has emerged as a promising platform owing to its natural capacity for high-level protein synthesis, favorable glycosylation profile, rapid flock expansion, and cost-effective large-scale production. The case for an alternative: Chicken egg Taken together, existing expression systems present a shared dilemma: prokaryotic and lower eukaryotic platforms offer cost and scalability advantages, but cannot reliably produce human-compatible glycoproteins, while mammalian and insect cell systems achieve a greater biological fidelity at the expense of substantial infrastructure investment and operational complexity. This trade-off motivates the search for a bioreactor that bridges biological authenticity and production economics and positions the chicken egg as a uniquely promising candidate, as detailed in the following sections. The chicken egg is a self-contained biological system uniquely suited for recombinant protein production. It comprises anatomically distinct compartments—the albumen, also called the egg white, and the yolk each housing a rich repertoire of endogenous proteins, including ovalbumin, ovo-transferrin, and lysozyme, collectively exceeding 40 mg/mL total protein. Critically, the egg’s biosynthetic machinery, concentrated in the liver (for yolk proteins) and oviduct epithelium (for albumen proteins), supports the full complement of eukaryotic post-translational modifications, including complex N-linked glycosylation with human-compatible sialylated glycans, disulfide bond formation, and proteolytic processing-precisely the biological capabilities that microbial and lower eukaryotic systems lack. Emergence of chicken bioreactor (historical perspective) The chicken egg has emerged as a recombinant protein bioreactor. What began as a proof-of-concept demonstration has since advanced to precise genome engineering strategies capable of producing therapeutic proteins at commercially relevant levels. The progress, however, has not been uniform: different transgenic approaches have yielded markedly different outcomes in germline transmission, transgene stability, tissue-specific expression, and recombinant protein yield. These variabilities have driven the field’s gradual shift from random transgene integration towards targeted genome editing (Lee et al., 2017). Harvey et al. (2002) provided the first convincing evidence that the avian oviduct could function as a protein production platform, achieving stable germline transmission and expression of Escherichia coli β-lactamase driven by the ubiquitous cytomegalovirus (CMV) promoter. Importantly, this study also validated the use of the replication-defective retroviral vector, showing no detectable avian leukosis virus (ALV) in transgenic birds, thereby addressing the biosafety concerns associated with earlier replication-competent reticuloendotheliosis virus (REV)-based systems used by Salter et al. (1986) and Bosselman et al. (1989). Although Harvey et al. established the feasibility of producing recombinant proteins in egg white, the CMV promoter produced relatively modest expression levels compared with later oviduct-specific expression strategies, illustrating that successful transgene integration alone does not ensure high protein production. Further investigations expanded the spectrum of recombinant proteins expressed in eggs to include human interferon-α2, interferon-β, erythropoietin, epidermal growth factor, defensins, antimicrobial peptides and monoclonal antibodies (Rapp et al., 2003; Kamihira et al., 2005; Lillico et al., 2007; Koo et al., 2010; Cao et al., 2015; Liu et al., 2015; Park et al., 2015; Oishi et al., 2018). Collectively, these studies confirmed that the avian oviduct can synthesize structurally diverse therapeutic proteins with appropriate folding and post-translational modifications. The introduction of primordial germ cell (PGC)-mediated transgenesis represented an important advance, enabling genetic modification of cultured germ cells prior to germline transmission. Compared with direct embryonic viral injection, PGC-based approaches improved founder generation, allowed molecular characterization before transplantation, and facilitated the establishment of stable transgenic lines (Van De Lavoir et al., 2006). However, outcomes for recombinant protein expression were less consistent: several groups observed improved germline transmission and line stability (Park and Han, 2012; Macdonald et al., 2012), whereas others reported only modest gain in recombinant protein yield, since most PGC-based studies relied on random viral or transposon-mediated integration. These observations indicate that although PGC technology effectively addressed limitations associated with founder production, it did not eliminate expression variability arising from uncontrolled transgene insertion. Thus, improvements in germ-cell engineering alone were not sufficient to achieve predictable, high-level protein expression (Mukae et al., 2021). The integration of programmable nucleases—particularly ZFNs, and TALENs—with PGC-mediated transgenesis substantially improved the precision and efficiency of generating genetically modified chickens. A major shift occurred with the introduction of programmable genome editing, particularly CRISPR/Cas9-mediated targeted knock-in at the endogenous ovalbumin (OVA) locus (Oishi et al., 2018). Unlike random integration, this strategy targets one of the most transcriptionally active loci in the avian genome, thereby minimizing position effects and improving expression consistency. Herron et al. (2018) demonstrated efficient oviduct-specific expression following OVA-locus knock-in, while subsequent studies reported production of therapeutic proteins, including human interferon-β, erythropoietin and adiponectin, at concentrations reaching tens to hundreds of milligrams per egg (Kwon et al., 2018; Kim et al., 2023a; Nishijima and Okuzaki, 2026). However, not all proteins achieved comparable expression despite identical genomic targeting, suggesting OVA-locus-specific insertion alone does not guarantee maximal productivity; protein-specific factors such as transcript stability, translation efficiency, intracellular processing and secretion remain critical determinants of final yield. Current evidence therefore supports targeted knock-in as the most reproducible strategy available, though not as a universal solution for all recombinant proteins. Among these technologies, CRISPR/Cas9 has become the preferred genome-editing platform owing to its simplicity, versatility and high editing efficiency, whereas TALENs remain useful to genomic regions less amenable to CRISPR guide RNA design. PGC-mediated transgenesis complements these editing tools by enabling genetic modification, molecular characterization and selection of germ cells in vitro prior to transplantation, thereby reducing founder variability and improving germline transmission. The translational credibility of the platform has been further cemented by regulatory milestones: Kanuma (sebelipase alfa), an enzyme replacement therapy for lysosomal acid lipase deficiency, and Epovet a veterinary erythropoietin product, have both received regulatory approval as egg-derived biopharmaceuticals—demonstrating that the chicken egg bioreactor can satisfy the stringent manufacturing, safety, and consistency standards required for clinical and commercial development. The progression of this field, from early transgenic constructs through site-specific genome editing to approved therapeutics, is systematically documented in Table 1, which consolidates the key parameters of reported egg-based expression studies, including the genetic modification strategies employed, promoter identity, target compartment, and protein yield achieved per egg. Fig. 3 complements Table 1 by graphically depicting the types of recombinant proteins expressed and their documented concentration levels in chimeric chicken eggs. However, these findings are difficult to interpret because of the lack of standardized experimental designs, as relatively few studies have systematically compared different promoters, genomic target loci, or genome-editing platforms under identical conditions. Consequently, it remains unclear whether differences in protein yield primarily reflect the editing technology employed, the genomic integration site, promoter selection, or intrinsic protein-specific factors such as folding, secretion efficiency and post-translational processing. Although targeted knock-in at endogenous oviduct-specific loci has consistently outperformed random integration strategies by reducing positional effects and improving expression reproducibility, homologous recombination efficiency in avian PGCs still remains lower than the mammalian stem-cell systems, and comprehensive evaluation of off-target editing, long-term genetic stability, biosafety and regulatory compliance is still lacking. Current evidence therefore strongly supports CRISPR/Cas9-mediated targeted genome editing as the most promising strategy for developing chicken bioreactors. Future studies should prioritize standardized head-to-head comparisons of genome-editing platforms and establish uniform criteria for reporting protein yield, biological activity and production scalability to enable objective evaluation of this technology for industrial biopharmaceutical manufacturing. Table 1Major foreign proteins expressed using chicken eggs as a bioreactor platform (Farzaneh et al., 2017; Woodfint et al., 2018; Meng et al., 2025).Foreign protein expressedSite of expressionPromoterVector method & plasmidYieldaReferenceβ-lactamaseEggwhite & serumCytomegalovirus (CMV)Chicken Leukosis Virus (pNLB-OV-CAT)0.47–1.34 µg/mLHarvey et al., 2002Human interferon-α2bEggwhiteCytomegalovirus (CMV)Chicken Leukosis Virus (pNLB-CMV IFN)2.7 µg/mLRapp et al., 2003Human interferon-βEggwhite & serumOvalbuminCRISPR/Cas9(pX330-Neo-OVATg1)1.86–3.52 mg/mL (egg white); 0.23–1.75 ng/mL (serum)Oishi et al., 2018Human interferon-β1a with an scFv-Fc fusion proteinEggwhite & serumOvalbumin (+ERE)Lentivirus (pGEMTeasy & pONY8.45Nmcs)38 µg/mLLillico et al., 2007Human erythropoietinEggwhite & serumβ-actinRetroviral vector (pMSCV/GΔAhEpo(c)W)7–40 µg/mLKodama et al., 2008Eggwhite & serumHuman PGK + tetracycline-inducible promoterGibbon ape leukemia virus (pTet2-EPO plasmid)300 IU/mL (serum); 1.8 IU/mL (egg white)Koo et al., 2010SerumCytomegalovirus (CMV)Moloney murine leukaemia virus (pLNC-hEPOW)90 µg/mLKoo et al., 2017EggwhiteOvalbuminFeline immuno-deficiency virus vector (pFIV-Ov19-hPOW & pCDF1-MCS2-EF1-Puro)40.1–55.0 µgKwon et al., 2018Human erythropoietin/Fc fusion proteinEggwhite, yolk & serumβ-actinVSV-G-pseudotyped retroviral vector (pMSCV/GΔAhEpo/Fc & pMSCV/GΔAhEpo/FcW)27–144, 9–66 and 12–41 µg/mL, respectivelyPenno et al., 2010Human growth hormoneNAOvalbuminRetroviral vector (pLG-OVA-hGH)NAKodama et al., 2012Human epidermal growth factorEggwhiteOvalbumin (+2 ERE)Injection of transformed PGCs (2×ERE-OVcEGF & GFP-OVcEGF)60 ng/mLPark et al., 2015Human parathyroid hormoneSerumRous Sarcoma Virus (RSV)Moloney murine leukaemia virus (pLNRhPTHW)17,830 pg/mLLee et al., 2007Human adiponectinEggwhiteOvalbuminCRISPR/Cas9 (pX459)1.47–4.59 mg/mLKim et al., 2023bAdiponectin (ADPN)EggwhiteOvalbuminCRISPR/Cas90.59 mgYoo et al., 2024Granulocyte-colony stimulating factorSerumCytomegalovirus (CMV)Retroviral vector (pLNC-GCSFW)∼3.4 mg/mLKwon et al., 2008Recombinant human interleukin-1 receptor antagonistEggwhiteOvalbuminLentivirus (pLTOKiGW)88.7–233.8 ng/mLKwon et al., 2010Tumor necrosis factor receptor/Fc fusion proteinEggwhite,yolk & serumβ-actinRetroviral vector (pMSCV/GΔA-TNFR/Fc & pQMSCV/GΔA-TNFR/FcW)200–350 µg/mL (serum); 25 µg/mL (yolk)Kyogoku et al., 2008Single-chain Fv–Fc fusion proteinEggwhite & serumRous Sarcoma Virus (RSV)Moloney murine leukaemia virus (pMSCV/GΔAscFv-Fc)5.6 µg/mLKamihira et al., 2005Eggwhite,yolk & serumβ-actinRetroviral vector (pMSCV/GΔAhEpo/Fc & pMSCV/GΔAhEpo/FcW)27–144, 9–66 and 12–41 µg/mL, respectivelyKawabe et al., 2006Human–mouse antibody specific for dansyl hapten (mAbdns) & prostate-specific membrane antigen antibody (mAbF1)EggwhiteOvalbuminTransgene-integrating vectors (Ov7.5mAbdns & Ov15mAbF1)≈3 mgZhu et al., 2005Heavy and light chains of chimeric anti-CD2 and anti-prion peptide monoclonal antibodiesEggwhite, yolk & serumβ-actinRetroviral vector (pMSCV/ΔALIH (CD2) & pMSCV/ΔALIH (PrP))8–30 µg/mL for anti-CD2; 64–350 µg/mL for anti-PrPKamihira et al., 2009Monoclonal antibodiesEggwhiteOvalbuminCRISPR/Cas9 (pX330-Puro-OVATg2)1.4–1.9 mg/mLMukae et al., 2020Human urokinase-type plasminogen activatorSerum & eggwhiteRous Sarcoma Virus (RSV)Moloney murine leukaemia virus (pLNRhuPAW)7.82–17.02 IU/eggLee et al., 2013Human lysozymeEggwhiteOvalbumin (+ERE)Lentivirus (pWPXL-EREOV-hLY)57.66 ± 4.10 µgCao et al., 2015Human neutrophil defensin 4EggwhiteOvalbuminLentivirus (Ova-HNP4, psPAX2, pMD2G)1.65–10.18 µg/mLLiu et al., 2015Green fluorescent protein (GFP)NAHuman PGK + tetracycline-inducible promoterMoloney murine leukaemia virus (pLNRGW)NAChul Koo et al., 2006NAOvalbuminLentiviral vector (pLenti6/R4R2/V5-DEST)NAByun et al., 2011NAOvalbuminCRISPR/Cas9 (pX330-U6-Chimeric_BB-CBh-hSpCas9 & pSLQ2814)NAShi et al., 2020Enhanced Green Fluorescent Protein (EGFP)NAOvalbuminCRISPR/Cas9 (pX459)165.25 ± 19.82 µg/mLKim, et al., 2023bNAOvalbuminCRISPR/Cas9 (pX330)4.96–9.86 mgXie et al., 2024Abbreviations: NA: not available; pg/mL: picogram per milliliter; ng/mL: nanogram per milliliter; µg/mL: microgram per milliliter; mg/mL: milligram per milliliter; IU: International Unit.ayields are reported as originally defined in the cited publications. Major foreign proteins expressed using chicken eggs as a bioreactor platform (Farzaneh et al., 2017; Woodfint et al., 2018; Meng et al., 2025). Abbreviations: NA: not available; pg/mL: picogram per milliliter; ng/mL: nanogram per milliliter; µg/mL: microgram per milliliter; mg/mL: milligram per milliliter; IU: International Unit. yields are reported as originally defined in the cited publications. Graphical representation of the types of recombinant proteins expressed and their documented concentration levels in chimeric chicken eggs. The plotted data comprise previously published measurements of protein type and concentration in terms of µg/mL per egg. Error bars indicate two different reported expression concentrations for the same protein. Dotted lines represent median protein concentration in the respective regions of the egg. The chicken advantage, limitations, and methods of transgenesis The biological and manufacturing advantages The chicken egg offers a constellation of biological properties that collectively address the most persistent bottlenecks of conventional recombinant protein manufacturing. The albumen is a remarkably simple protein matrix dominated by a small number of abundant species, principally ovalbumin, ovotransferrin, ovomucoid, and lysozyme which substantially reduces the purification burden compared to the complex conditioned media of mammalian cell cultures, where hundreds of secreted host cell proteins must be resolved from the product of interest. Furthermore, the egg is a naturally sterile, sealed biological unit with inherent buffering capacity, properties that extend the stability and shelf life of expressed recombinant proteins without the need for cold-chain-intensive formulation strategies. From a glycobiology standpoint, the chicken egg presents a particularly compelling profile for therapeutic glycoprotein production. Like humans, chickens do not express the enzyme CMP-Neu5Ac hydroxylase and therefore lack N-glycolylneuraminic acid (Neu5Gc), a non-human sialic acid, prominently displayed on glycoproteins produced in CHO and other rodent-derived mammalian cell lines that is associated with immunogenic responses in human patients (Nishijima and Okuzaki, 2026). Instead, both chickens and humans predominantly utilize N-acetylneuraminic acid (Neu5Ac), conferring chicken-derived glycoproteins with a fundamentally more human-compatible immunological character. This distinction is not trivial Neu5Gc incorporation into therapeutic proteins produced in mammalian systems has been identified as a potential driver of anti-drug antibody formation, a problem the egg-based platform circumvents by default. However, an important glycobiological nuance tempers this advantage. While the chicken's sialic acid repertoire mirrors that of humans, the albumen compartment itself has limited sialylation capacity; endogenous egg white glycoproteins carry truncated N-glycans that lack terminal sialic acid residues. For therapeutic proteins whose pharmacokinetics, receptor binding, or serum half-life depend critically on terminal sialylation, such as erythropoietin and other glycoprotein hormones this represents a genuine limitation requiring glycoengineering solutions, discussed further in a section below. Finally, because the chicken egg bioreactor system is inherently free from mammalian pathogens, prions, and human-tropic viruses, eliminating the biosafety surveillance burden that accompanies CHO and HEK293-based manufacturing and offering a regulatory simplification of considerable practical value (Herron et al., 2018). Limitations and unresolved challenges Despite its biological promise, the chicken egg bioreactor faces a set of practical and biological constraints that must be acknowledged candidly. The most significant operational limitation is the time required to establish a productive transgenic flock. Following successful genetic modification of primordial germ cells and generation of chimeric founder birds, chickens must reach sexual maturity typically at five to six months of age, before the first transgenic eggs can be harvested and evaluated. Subsequent backcrossing to confirm stable germline transmission and achieve homozygosity further extends the timeline to commercially meaningful production, placing the egg bioreactor at a temporal disadvantage relative to cell culture systems where production can commence within weeks of stable transfection. Maintaining a transgenic flock introduces additional operational vulnerabilities. Unlike closed bioreactor vessels, living animals are susceptible to infectious disease outbreaks, including avian influenza, Newcastle disease, and Marek's disease, which can decimate an entire production flock irreversibly, representing both a biosecurity risk and a business continuity threat. The cost of biosecure housing, veterinary surveillance, and animal husbandry further erodes the economic advantage over cell culture systems at smaller production scales. At the molecular level, a persistent challenge in PGC-mediated transgenesis is the competition between endogenous and exogenously introduced germ cells within the recipient embryo. Residual host PGCs in the gonadal niche dilute the contribution of genetically modified donor PGCs, limiting the degree of germline chimerism and, consequently, the frequency of transgenic offspring in the G1 generation. Strategies to ablate endogenous PGCs including busulfan treatment and immune depletion have been explored to improve colonization efficiency, though none has yet achieved complete and consistent replacement. Collectively, these limitations underscore the need for refined in vivo transgenesis approaches and improved PGC enrichment protocols that can reduce lead times, lower husbandry costs, and maximize germline transmission fidelity. Methods of generating transgenic chickens: from early transgenesis to precision genome editing The generation of transgenic avian bioreactors requires the successful integration of four interdependent components: an efficient gene delivery system, a biologically competent germline platform, stable genomic integration, and sustained tissue-specific transgene expression. The evolution of avian transgenesis reflects a gradual transition from random integration technologies toward precise genome engineering that seeks to improve reproducibility, germline transmission, and predictable recombinant protein expression. Early transgenesis: viral vectors and random integration Replication-competent retroviral vectors derived from avian leukosis virus (ALV) and reticuloendotheliosis virus (REV) provided the first successful demonstration of avian germline transgenesis following microinjection into stage-X blastoderm embryos (Salter et al., 1986). These pioneering studies established that foreign DNA could be transmitted through the avian germline, representing a landmark achievement in avian biotechnology. However, the continued production of infectious viral particles resulted in persistent viremia in founder birds, making replication-competent vectors unsuitable for agricultural or biopharmaceutical applications. The development of replication-defective retroviral vectors significantly improved the safety of avian transgenesis by eliminating the risks associated with replication-competent viral vectors. Bosselman et al. (1989) first demonstrated stable germline transmission using a defective reticuloendotheliosis virus (REV) vector. This approach was further refined by Thoraval et al. (1995) and Harvey et al. (2002), who developed the ALV-derived NLB vector by deleting ∼85% of the viral genome, thereby reducing biosafety concerns while maintaining its ability for transgene delivery. However, these vectors still exhibited random genomic integration and variable transgene expression. Early investigations into the manipulation of avian primordial germ cells established the conceptual basis for using PGCs as a vehicle for germline modification (Simkiss, 1991), which was subsequently demonstrated experimentally through transfer of genetically modified PGCs into recipient embryos (Vick et al., 1993). Using the PGC platform, Mozdziak et al. (2003) demonstrated stable transgene expression using a replication-defective spleen necrosis virus (SNV) vector, while Kamihira et al. (2005) and Kodama et al. (2008) established transgenic chickens as promising bioreactors by producing functional recombinant proteins in egg white. Despite these important advances, retroviral systems consistently produced highly variable biological outcomes. Germline transmission rates were generally low, founder birds were frequently mosaic, and transgene expression often declined in subsequent generations. These inconsistencies were primarily attributable to random genomic integration, which exposed transgenes to chromosomal position effects, insertional mutagenesis, variable copy number, and epigenetic silencing. Consequently, although retroviral vectors established the feasibility of avian transgenesis, they also revealed that efficient gene delivery alone was insufficient to ensure stable or predictable transgene expression. Lentiviral vectors: improved delivery but persistent variability The introduction of lentiviral vectors represented the first major technological breakthrough beyond conventional retroviral systems. Unlike retroviruses, lentiviruses efficiently transduce both dividing and non-dividing cells and are associated with a superior biosafety profile, and an ability to accommodate larger transgene cassettes. Using an equine infectious anemia virus (EIAV)-based lentiviral vector, McGrew et al. (2004) reported germline transmission efficiencies of ∼45%, representing a substantial improvement over previous retroviral methods and established lentiviral transgenesis as the predominant viral platform for poultry biotechnology. Subsequently, Chapman et al. (2005) generated chickens with stable EGFP expression, whereas Lillico et al. (2007) successfully produced human monoclonal antibodies in egg white, providing one of the earliest demonstrations that the chicken oviduct could function as a bioreactor for pharmaceutical protein production. In 2009, Xu et al. generated transgenic chickens expressing enhanced green fluorescent protein (EGFP) using third-generation self-inactivating (SIN) HIV-based lentiviral vectors (Liu et al., 2009; Xu et al., 2009). Additional studies subsequently reported lentiviral-mediated expression of recombinant human interferon-β, erythropoietin, and other therapeutic proteins, confirming the commercial potential of transgenic chickens for molecular farming. Nevertheless, the literature reveals considerable variation in recombinant protein yield and germline transmission among independently generated founder lines. Even when identical lentiviral vectors were used, some laboratories reported stable, high-level expression, whereas others observed pronounced inter-line variability or progressive transgene silencing. These conflicting outcomes primarily reflect the continued reliance of lentiviral vectors on random genomic integration. Differences in chromosomal insertion sites, transgene copy number, local chromatin architecture, and epigenetic regulation frequently overshadowed improvements in viral delivery efficiency. Thus, while lentiviral vectors substantially improved gene transfer, they did not eliminate the biological unpredictability inherent to random integration. Extending lentiviral transgenesis to other avian species Although chickens remain the principal species for avian biopharming, lentiviral technology has also been successfully adapted to other avian models, particularly Japanese quail (Coturnix japonica). Owing to its short generation interval, early sexual maturity, and ease of embryo manipulation, the Japanese quail has become an important model for developmental biology, neurobiology, and functional genomics. In this context, Mizuarai et al. (2001) produced transgenic quails with high frequency of germline transmission using VSV-G pseudotyped retroviral vector. Later, Shin et al. (2008) generated germline transgenic quail using lentivirus transduced gonadal PGCs, demonstrating efficient germline transmission and stable inheritance of the introduced transgene. Subsequently, Scott and Lois (2005) developed an alternative strategy based on intravascular microinjection of lentiviral vectors into Hamburger–Hamilton stage 13–15 embryos rather than conventional Stage X blastoderm injection. This approach achieved approximately 13% germline transmission while simplifying embryo manipulation and improving embryo survival. Besides facilitating transgenic quail production, these studies established Japanese quail as a valuable complementary model for investigating vertebrate development and neural crest biology. More recently, Naseri et al. (2021) demonstrated that germline transmission is influenced not only by vector design but also by the developmental stage of viral delivery. By systematically comparing injections into the blastoderm, embryonic dorsal aorta, and chorioallantoic membrane (CAM), the authors showed that conventional blastoderm injection produced only 0.4% germline transmission, whereas embryonic bloodstream injection increased transmission to 7.7%. The highest efficiency (13.6%) was achieved by combining dorsal aorta and CAM injections. These findings explain, at least in part, the conflicting germline transmission efficiencies reported by earlier studies and demonstrate that successful modification depends on targeting PGCs during their migratory phase rather than solely on improvements in viral vector design. Although lentiviral vectors remain among the most efficient viral vector systems, their dependence on random genomic integration continues to generate substantial founder-to-founder variability. Consequently, advances in embryo manipulation have improved germline transmission but have not fully resolved variability in transgene expression. Non-viral integration systems: increased flexibility but random insertion persists In parallel with viral technologies, several non-viral approaches were developed to reduce biosafety concerns associated with viral vectors. Direct plasmid microinjection, electroporation, lipofection and sperm-mediated gene transfer enabled rapid assessment of gene function during embryogenesis and proved valuable for developmental biology studies (Love et al., 1994; Muramatsu et al., 1997; Naito et al., 1998; Nakamura and Funahashi, 2001; Sato et al., 2007;Sauka-Spengler and Barembaum, 2008; Kaleri et al., 2011). However, these approaches generally produced transient expression and exhibited poor or inconsistent germline transmission, limiting their utility for generating stable transgenic poultry. The main factors responsible for variation in exogenous gene integration and expression were pulse amplitude, pulse duration, the number of delivered pulses, and osmotic pressure. DNA transposons represented a significant improvement by facilitating permanent genomic integration without viral components. Tol2 and piggyBac, in particular, accommodated relatively large transgene cassettes and demonstrated efficient genomic integration in chickens and Japanese quail (Poynter et al., 2009; Sato et al., 2010; Macdonald et al., 2012; Park et al., 2012). PiggyBac subsequently became widely adopted for genetic manipulation of cultured chicken PGCs because of its high transposition efficiency. Despite these advantages, transposon-based systems produced inconsistent recombinant protein expression among independent founder lines. Since both Tol2 and piggyBac integrate semi-randomly throughout the genome, transgene expression remained strongly influenced by local chromatin structure and insertion site. Consequently, although transposon approaches improved integration efficiency relative to plasmid DNA, it did not fundamentally overcome the biological limitations associated with random integration. Promoter selection: an overlooked determinant of recombinant protein production While considerable attention has focused on vector development, accumulating evidence indicates that promoter selection is equally important in determining transgene performance. Constitutive promoters such as CMV, CAG, EF1α, and chicken β-actin typically produce robust expression during embryogenesis and in cultured cells but often undergo progressive methylation and transcriptional silencing in differentiated tissues or after germline transmission. Consequently, several studies have reported marked reductions in transgene expression despite successful genomic integration. By contrast, tissue-specific promoters exploit endogenous regulatory networks to achieve spatially restricted expression. The most successful example is the chicken ovalbumin promoter. Byun et al. (2011) demonstrated that EGFP driven by the endogenous ovalbumin promoter was expressed specifically in the tubular gland cells of the magnum and inherited through the germline, providing the first convincing proof-of-concept for oviduct-specific expression in transgenic chickens. Subsequent targeted knock-in studies at the ovalbumin locus further confirmed that preservation of native cis-regulatory elements results in more predictable, stable, and higher recombinant protein production than random integration driven by heterologous constitutive promoters. These observations explain why identical therapeutic proteins have frequently been reported at markedly different expression levels despite the use of similar delivery vectors. Biological platforms: why primordial germ cells became the preferred system Perhaps the most important conceptual advance in avian transgenesis was the transition from embryo-based manipulation to germline cell engineering. Early approaches relied on blastoderm embryos, embryonic stem cells, or sperm-mediated gene transfer, all of which suffered from poor germline competence, mosaicism, and inconsistent transmission. In contrast, the establishment of long-term cultured chicken PGCs by van de Lavoir et al. (2006) transformed avian genome engineering by providing a stable, expandable, and genetically tractable germline cell population. Cultured PGCs offer several advantages over previous biological platforms. They can be clonally expanded, genetically screened, cryopreserved, and precisely modified before transplantation into recipient embryos, thereby eliminating much of the biological variability associated with direct embryo manipulation. Consequently, only correctly edited germ cells contribute to the germline, substantially improving reproducibility and founder quality. These characteristics explain why cultured PGCs rapidly replaced blastoderm cells and embryonic stem cells as the preferred platform for avian genome engineering (Nayga et al., 2025). Long-term culture studies have demonstrated that chicken gonadal PGCs can be maintained in vitro for extended periods while retaining characteristic germ-cell markers, normal karyotype, pluripotency-associated properties, and the capacity to migrate to the developing gonads following transplantation (Kong et al., 2018). Subsequent studies have further demonstrated that genetically modified PGCs can contribute to functional gametes and transmit introduced genetic material to offspring, although germline transmission efficiency varies substantially depending on PGC quality, genetic modification strategy, recipient embryo condition, and competition with endogenous PGCs (Park and Han, 2012). Thus, the principal advantage of PGC-mediated transgenesis is not necessarily a uniformly high germline transmission rate, but rather the ability to genetically modify, expand, characterize, select, and cryopreserve germ cells in vitro before their introduction into recipient embryos. These characteristics substantially improve experimental control and reproducibility compared with direct embryo manipulation and make PGCs an important platform for establishing genetically modified chicken lines for bioreactor applications. Precision genome editing: overcoming the limitations of random integration The development of programmable nucleases marked the transition from random integration to targeted genome engineering. Zinc-finger nucleases (ZFNs) and TALENs first demonstrated efficient site-specific genome modification in cultured chicken PGCs (Schusser et al., 2013; Park et al., 2014; Taylor et al., 2017), but both technologies required extensive protein engineering for every genomic target, limiting widespread application. Use of CRISPR/Cas9 technology fundamentally transformed avian transgenesis by providing a simple, RNA-guided system capable of efficient gene knockout, multiplex editing, and targeted knock-in. Integration of recombinant protein expression cassettes into the endogenous ovalbumin locus substantially reduced variability associated with position effects and generated more predictable tissue-specific expression than viral or transposon-mediated random integration (Oishi et al., 2016; Dimitrov et al., 2016; Lee et al., 2019). Nevertheless, differences in donor design, homology arm length, DNA repair pathway activity, and PGC quality continue to influence knock-in efficiency among laboratories, indicating that further optimization remains necessary for industrial-scale biopharming. Emerging technologies, including base editing and prime editing (Komor et al., 2016; Gaudelli et al., 2017; Anzalone et al., 2019), further expand the genome engineering toolbox by enabling precise nucleotide substitutions without introducing double-strand DNA breaks. Although their application in poultry remains in its infancy, these systems offer considerable promise for introducing disease-resistance alleles and optimizing production traits while minimizing unintended genomic alterations. Translational impact and future trajectory The convergence of precision genome editing, PGC biology, and oviduct-specific expression systems has elevated the chicken egg from a biological curiosity to a credible biopharmaceutical manufacturing platform. With two egg-derived therapeutics, Kanuma and Epovet, already carrying regulatory approval and an expanding portfolio of recombinant proteins demonstrated at milligram-per-milliliter yields in albumen, the platform has crossed the threshold from proof-of-concept to translational reality. Looking forward, the integration of glycoengineering strategies to address the sialylation gap, combined with advances in biosecure poultry management and accelerated sexual maturation protocols, has the potential to position the chicken egg bioreactor as a genuine complement and, in certain contexts, a superior alternative to existing manufacturing paradigms, particularly for applications requiring low-cost, large-volume production of glycoprotein therapeutics in resource-limited settings. The complete workflow from transgenic founder generation to commercial egg harvest is illustrated in Fig. 2. Workflow for recombinant protein production using genome-edited chicken primordial germ cells (PGCs). PGCs are isolated, cultured, genetically modified, screened, reintroduced into recipient embryos, and used to generate transgenic chickens producing recombinant proteins in egg white. Conclusion and future directions The evidence reviewed in this article builds a compelling case that the chicken egg has matured from an experimental curiosity into a scientifically validated, translationally credible platform for recombinant therapeutic protein production. The convergence of three independent lines of progress—precision genome editing through CRISPR/Cas9-mediated PGC transgenesis, the intrinsic biological suitability of the chicken oviduct as a high-capacity protein secretory tissue, and the demonstrated regulatory approvability of egg-derived biopharmaceuticals has collectively elevated this system beyond proof-of-concept and into the frontier of next-generation bio-manufacturing. The platform's most consequential advantage is not simply economic, though the cost differential relative to CHO cell-based manufacturing is substantial and well-documented (Rathore et al., 2024). Rather, it is the combination of human-compatible glycosylation chemistry specifically, the absence of immunogenic Neu5Gc and the predominance of Neu5Ac with the egg's natural sterility, protein-rich matrix, and inherent freedom from mammalian pathogens that makes it biologically distinctive among available expression systems. The regulatory approval of Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency and Epovet as a veterinary erythropoietin have demonstrated unambiguously that egg-derived recombinant proteins can satisfy the stringent manufacturing consistency, safety, and efficacy standards required for clinical deployment. Equally significant is the emergence of purpose-driven biotechnology ventures such as Neion Bio, whose translational work signals that the historically perceived barriers of this platform—long founder-generation timelines, flock biosecurity, and regulatory novelty are being systematically resolved at the commercial level. Nevertheless, several scientific and operational challenges must be addressed before the chicken egg bioreactor can fulfil its potential as a mainstream manufacturing platform. The most pressing biological limitation remains the incomplete sialylation of recombinant glycoproteins expressed in egg white, which constrains the platform's current applicability to glycoprotein therapeutics whose pharmacokinetics depend on terminal sialic acid residues, such as erythropoietin and thrombopoietin. Addressing this will require either glycoengineering of the oviduct secretory pathway through co-expression of human sialyltransferases under oviduct-specific promoters or post-harvest enzymatic sialylation of the purified product. Both strategies are technically feasible and represent a defined near-term research priority (Senra et al., 2024). Concurrently, the extended timeline from transgenic founder generation to productive flock establishment, currently spanning six to twelve months, represents a structural disadvantage relative to cell culture systems. Accelerated sexual maturation protocols, in combination with improved endogenous PGC depletion strategies to maximize germline chimerism in recipient embryos, offer realistic routes to compressing this timeline significantly. Looking forward, several emerging directions hold particular promise. First, the application of multiplexed CRISPR editing to simultaneously knock-in therapeutic transgenes and knock-out endogenous egg white proteins such as ovalbumin could both increase the fractional abundance of recombinant product and simplify downstream purification, addressing two manufacturing challenges in a single genomic intervention. Second, the development of inducible oviduct-specific promoter systems would enable temporal control over recombinant protein expression, reducing the metabolic burden on hens during developmental periods and potentially improving flock longevity and productivity. Third, the integration of the chicken egg platform with continuous bioprocessing strategies including automated egg collection, in-line quality monitoring, and affinity-based capture systems designed for albumen matrices would bring the operational workflow closer to the process analytical technology frameworks that regulatory agencies increasingly expect of modern biopharmaceutical manufacturing. From a global health equity perspective, the chicken egg bioreactor carries an obligation that extends beyond technical performance metrics. The platform's low infrastructure requirements, compatibility with existing poultry industry supply chains, and potential for distributed manufacturing make it uniquely suited to reducing the chronic inaccessibility of recombinant protein therapeutics in low and middle-income countries—a structural inequity that conventional mammalian cell manufacturing has failed to resolve despite decades of incremental optimization (Rathore et al., 2024). Realizing this potential will require deliberate investment in regulatory pathway development for egg-derived biologics in emerging market jurisdictions, technology transfer frameworks that enable local production capacity, and health economic analyses that make the cost-benefit case to national procurement agencies. In summary, the chicken egg bioreactor stands at an inflection point. The scientific foundations are robust, the translational precedents are established, and the unmet need it addresses— affordable, scalable, biologically authentic recombinant protein production—is both large and growing. The principal work that remains is not one of fundamental discovery but of systematic engineering refinement, regulatory maturation, and deliberate deployment toward the populations who stand to benefit most. The feathered bioreactor, in this light, is not merely a technical novelty; it is a platform with genuine transformative potential for global biopharmaceutical access. Ethics declaration The author(s) declare(s) that the study does not involve humans nor animal subjects. Author Contribution Adnan Naim: Conception and designing of the work, acquisition of data and analysis, writing, reviewing, and final revision of the draft. Accountable for all aspects of the information presented in the final version of the draft. Arjun Sharma: Drafting of the review article, data analysis & Fig. preparation, critically reviewing the final version of the manuscript. Accountable for all aspects of the information presented in the final version the draft. Sanket Kumar Ray: Drafting of the review article, data analysis, Fig.s and table preparation, revision of the final version of the draft. Accountable for all aspects of the information presented in the final version of the draft. Debasis Nayak: Conception and framework designing of the article, proof-reading the final revised version and explicitly approving the exact, final version of the manuscript before it goes to press. Accountable for all aspects of the information presented in the final version of the draft. Disclosures The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Debasis Nayak reports financial support was provided by Indian Institute of Science Education and Research Bhopal. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments The authors would like to thank Anusandhan National Research Foundation (ANRF), Govt. of India for providing funding through the project (SPR/2023/000205). The authors would like to extend their gratitude to the Director IISER, Bhopal. Footnotes Appropriate scientific section for the paper: Molecular and Cellular Biology References